About Us
Redefining Possibilities In Biomaterials
NOVUS at a Glance
Novus Life Sciences Limited is a global biomedical company specialising in the development and manufacture of medical grade 3D printing biomaterials for clinical and research applications. We have grown into an internationally recognised supplier of ISO 13485 certified filaments and patient-specific implant solutions, trusted by hospitals, surgical centres, universities, and medical device manufacturers.
Our flagship product, Bonlecule, is the world's only bioactive FDM filament for permanent bone implants. Alongside our broader portfolio of medical grade PEEK, PMMA, PLLA, PC, and PETG filaments, we provide comprehensive support from material selection through to printing optimisation and clinical application guidance.
2000+
annual cases
60+
countries reached
160+
clients
12
years of experience
Our Mission
To bridge clinical needs and laboratory innovation by developing and manufacturing medical grade 3D printing biomaterials and patient-specific implant solutions that are safe, accessible, and scalable for global clinical applications.
Our Vision
To transform healthcare by becoming the world's most trusted leader in translating biomaterial science into innovative, clinically proven medical devices, improving patient outcomes for both humans and animals worldwide.
Sites and Facilities
Our sites are purpose-built for medical device production and are equipped with advanced quality control infrastructure.
ISO cleanroom certification
Our production facilities meet ISO 14644-1 Class 5 (Class 100) standards, with most process areas maintained at Class 6 (Class 1,000). This controlled environment ensures standardised, contamination-free production of medical grade filaments and implant components that meet the stringent requirements of hospital procurement and regulatory bodies worldwide.
R&D to Industrial Scale
Our scientists and engineers specialise in biomaterial synthesis and nano-coating technology, translating laboratory protocols into validated production SOPs. With both research and manufacturing equipment on-site in Hong Kong, we accelerate the journey from innovation to market-ready medical grade products — a process that in conventional pharmaceutical or device manufacturing can take years.
One-Stop Medical Device Production
Each Novus facility supports full-cycle medical device manufacturing and packaging, with in-house quality assurance including Tyvek seal peel testing to ensure product integrity during transport and storage. This end-to-end capability means hospitals and distributors receive products that are ready for clinical use upon arrival.
In-House Ethylene Oxide Sterilization
To guarantee patient safety, Novus performs in-house ethylene oxide (EtO) sterilisation as a standard part of our production SOP. This in-house capability minimises contamination risk at every stage and eliminates the delays and traceability gaps associated with third-party sterilisation providers.
Collaboration & Partnership
Over the years, Novus Life Sciences has built a global network of hospital partners, research institutions, and industry investors committed to advancing medical 3D printing. With backing from respected statutory bodies and venture capitalists across Asia, Europe, and the Americas, Novus has expanded beyond filament manufacturing into a group of companies engaged in biomaterial R&D, contract manufacturing, technology consultancy, and clinical services.
Our partners include world-renowned institutions such as the University of Oxford, National University Hospital Singapore, Nanyang Technological University, and Mayo Clinic. These partnerships reflect the clinical trust placed in our materials and the strength of our technical support across diverse surgical specialties.
